In the past decade, lung cancer treatments have generally focused on targeted therapies such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) fusion protein inhibitors. Here, EGFR is linked to lung carcinoma.